Michael Bonney

Last updated
Michael Bonney
Michael Bonney, May-2014.gif
Bonney as chief executive of Cubist Pharmaceuticals
Born
Michael Weston Bonney
NationalityAmerican
Alma mater Bates College
Occupations
Years active1984 - present
Employers
Board member of
SpouseAllison Grott Bonney

Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion. [1]

Contents

Bonney, a native of the Greater Boston area, graduated from Bates College before entering the pharmaceutical industry. He was hired by Biogen in 1995 eventually becoming the company's vice president for Sales and Marketing. During his tenure at the company he developed Avonex, which was according to MarketWatch , one of the most successful drugs in biotechnology history. He was appointed the chief operating officer of Cubist Pharmaceuticals in 2003 and served in the position for one year before becoming chief executive. His tenure as CEO saw mixed profit levels, criticism, and increased market volatility as well as the development and release of Cubicin, the most profitable launch of an antibiotic in the history of the United States. [2]

Bonney serves as an advisor to former Prime Minister David Cameron's Commission on Antimicrobial Resistance (AMR). [3]

Early life and education

Bonney graduated from Bates College in Lewiston, Maine with Artium Baccalaureus (A.B.) degree in Economics in 1980. [4]

Business career

Early career

Bonney began his formal business career after graduating from Bates in 1984 in small pharmaceutical startups, before leaving the companies in various sales management positions. In 1995, he joined Biogen, where he rose through management positions to vice president for Sales and Marketing, a position he held from 1999 to 2001. At the company, "he built the commercial infrastructure for the launch of Avonex, an injectable biologic therapy for the treatment of multiple sclerosis. He held various positions in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career and served as its National Business Director." [2] His launch of Avonex, was one of the most successful drugs in biotechnology history, having sold well over market projections. [5]

Cubist pharmaceuticals

Bonney served as the chief operating officer of the company from January 2002 to June 2003. [2] In many media profiles, his first days at Cubist received mixed profit levels and failed to reach the same financial success as his work at Biogen. His first attempt at a launch failed with its first produce not passing the primary clinical trial. Cubist's stock decreased at a considerable rate which forced the company to make market rearrangements.

His second attempt, Cubicin, was a commercial success. His launch of the I.V. antibiotic, received media attention for being most profitable launch of an antibiotic in the history of the United States. [2] In May 2009, Bonney and his company was named the best company and best CEO in Massachusetts, respectively. [6]

In later 2010, over all sales for the drug hit near $625 million. The drug quickly gained the approval of the Food and Drug Administration and generates over $1 billion in sales annually. [7]

As chief executive

Bonney was awarded the MASSBio Innovative Leadership Award in 2010. [2] Shortly after his award, Cubist appeared on Fortune 2010's List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500. [8] In 2011, in an interview with New England Cable Network's business show CEO Corner, he outlined his development philosophy.

Let's separate out discovery from development, on the development side, absolutely it helps [to have successfully developed a drug]. We understand how to interact with regulators and what they want to see from a new antibiotic that has activity against resistant bacteria. On the discovery side, you’re talking about an incredibly complex set of problems that you have to deal with. I’m not sure that having one success means you will have a string of them. We have expertise, so we increase the odds, but finding new antibiotics, keeping ahead of the bacteria, is really hard work. [9]

In January 2012, Bonney was profiled by Market Watch in a piece entitled, "Nothing bugs Cubist CEO Michael Bonney", which outlined his contributions to the company from its start with mixed results followed by his turning it around into "a $2.5 billion rising star." [5] His launch of the I.V. antibiotic, Cubicin, received media attention for being most profitable launch of an antibiotic in the history of the United States. [2] In July 2013, he agreed, along with his leadership team to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion. [10]

Bonney received a total annual compensation as CEO of $6.6 million; [11] $750,000 as base salary, $840,000 as bonuses, $2,499,998 in stock options, $2,499,998 in awarded stock, and $16,953 in other compensation. [12]

In 2014, succeeding Michael Bonney as president, Robert J. Perez, was announced to take leadership on January 1, 2015. [13] [14] In January 2015, Cubist Pharmaceuticals was sold to Merck & Co, for a total of $9.5 billion. [15] Bonney left the company as CEO tracked to reach $2 billion in sales and to expand the revenue stream of its flagship drug Cubicin. [10] He left the company with an estimated $30,364,448 in accumulated compensation. [16]

Post-Cubist activities

Bonney joined Boston-based company Third Rock Ventures as a partner in early 2015 [17] and left in late 2016. [3] His position encompassed guiding start up companies to financial viability and encourage marketplace completion in the field of bio medicine. [18] He gave angel funds to a start up called X4 Pharmaceuticals in late 2014. [19]

Upon his retirement Bonney was appointed to numerous boards including NPS Pharmaceuticals, Inc. in which he served as Director from January 2005 to February 21, 2015. He served as a Director of TerraGen Discovery, Inc. since June 11, 2003. [2] He also served as a Member of Biogen's clinical development review board "for the development of natalizumab for treating multiple sclerosis, Crohn's disease, and rheumatoid arthritis." [2]

He was appointed the chairman of the board of Alnylam Pharmaceuticals in December 2015. [2] [20] His chairmanship at Alnylam was coupled with a total compensation of $110,000 in base pay, $112,160 in awarded stock, and $1,580,877 in stock options; overall he has sold $12,486,091 in awarded stocks in the company. [21]

Personal life

Bonney lives with his wife, Alison Grott Bonney, in Boston, Massachusetts. [22] Bonney serves as a trustee of his alma mater, Bates College, and in 2016, he along with his wife, Alison ('80, also a trustee), gave the college a total of $10 million, the largest donation by a single party in the history of the college. [23] [24] A year later, he donated $50 million in support of the "Bates+You" fundraising campaign, the largest donation ever received by Bates and one of the biggest among liberal arts colleges. [25] [26] [27] Bonney has a four-generational lineage with the college. [28] [29] He currently serves on the board of Rare, an international conservation organization. [30]

Awards and honors

See also

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed briefly by US-based Pfizer. Teva regained its market leader position once Pfizer spun off its generic drug division in a merger with Mylan, forming the new company Viatris at the end of 2020. Overall, Teva is the 18th largest pharmaceutical company in the world.

James L. "Jim" Vincent was the chairman and CEO of Biogen Idec from 1985 to 2002. He graduated from Duke University's Pratt School of Engineering in 1961 with a Bachelor of Science degree, and received an MBA from the Wharton School of Business at the University of Pennsylvania in 1963. He was a member of the board of directors of Alnylam Pharmaceuticals and served as a trustee of Duke University for 12 years. He had two children, Aimee (Vincent) Jamison and Christopher Vincent.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Glenmark Pharmaceuticals</span> Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

<span class="mw-page-title-main">J. Michael Pearson</span>

J. Michael Pearson is a Canadian American pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.

<span class="mw-page-title-main">Cubist Pharmaceuticals</span> Defunct American pharmaceutical company

Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.

Trius Therapeutics was a biopharma company based in San Diego, CA that focused on the development of antibiotics.

<span class="mw-page-title-main">Vicki Sato</span> American biologist

Vicki L. Sato is a retired professor of management practice at Harvard Business School and a professor of the practice in the department of molecular and cell biology at Harvard University. Since 2021, she has been a member of the President’s Council of Advisors on Science and Technology (PCAST).

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

Optimer Pharmaceuticals Inc was a biopharmaceutical company, originally headquartered in San Diego, California, and later moved to Jersey City, New Jersey, United States.

Arrakis Therapeutics is a Waltham, Massachusetts-based biopharmaceutical company developing drugs for neurological disorders and other diseases. The company was co-founded in 2015 by Jennifer Petter, PhD, now Chief Innovation Officer Raj Parakh, Alan Walts and Henri Termeer. Arrakis has been led since October 2016 by CEO Michael Gilman, PhD, a former Biogen executive who co-founded and led Padlock Therapeutics and Stromedix.

James C. “Jim” Mullen was the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started he would retire from the board at the end of his term. In 2011, he was named CEO to drug manufacturer Patheon, based in Durham, North Carolina, as well as to their board. He stayed there until August 29, 2017.

George A. Scangos was a pharmaceutical executive and former chief executive officer of Vir Biotechnology from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. Prior to joining industry, Scangos was a professor of biology at Johns Hopkins University.

References

  1. ↑ "Ex-Cubist CEO Bonney named Third Rock partner - The Boston Globe". BostonGlobe.com. Retrieved 2016-11-28.
  2. 1 2 3 4 5 6 7 8 9 10 "Michael W. Bonney B.A.: Executive Profile & Biography - Businessweek". www.bloomberg.com. Retrieved 2016-05-23.
  3. 1 2 "Mike Bonney | Magenta Therapeutics". Magenta Therapeutics. Retrieved 2017-11-25.
  4. ↑ "Bates board chair Bonney '80 named a top U.S. CEO by MarketWatch". www.bates.edu. Retrieved 2016-05-23.
  5. 1 2 Kennedy, Val Brickates. "Nothing bugs Cubist CEO Michael Bonney". MarketWatch. Retrieved 2016-05-23.
  6. 1 2 "The Boston Globe ranks Cubist, with Bonney '80 as CEO, as No. 1 best business". www.bates.edu. Retrieved 2016-05-23.
  7. ↑ "Cubist CEO Bonney Steps Down After 12-Year Stint | Xconomy". Xconomy. 2014-10-20. Retrieved 2016-05-23.
  8. ↑ "100 FASTEST-GROWING COMPANIES". CNN. 2010. Retrieved 28 May 2011.
  9. ↑ "Cubist CEO Mike Bonney '80 talks about careers and superbugs with NECN". www.bates.edu. Retrieved 2016-05-23.
  10. 1 2 Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
  11. ↑ "Top CEO Salaries in Massachusetts". Mass Business Blog. 2015-05-04. Retrieved 2016-05-24.
  12. ↑ Salary.com, Site built by. "Compensation Information for Michael Bonney , CEO of CUBIST PHARMACEUTICALS INC | Salary.com". Salary.com. Retrieved 2016-05-24.
  13. ↑ Weisman, Robert (20 Oct 2014). "New Cubist Pharmaceuticals chief executive will be Robert J. Perez". www.BostonGlobe.com. Retrieved 23 Nov 2014.
  14. ↑ "Bonney to retire as CEO of Cubist, current COO to take over - Boston Business Journal". Boston Business Journal. Retrieved 2016-05-23.
  15. ↑ "Independent No More: Cubist Sold to Merck for $9.5B | Xconomy". Xconomy. 2014-12-08. Retrieved 2016-05-23.
  16. ↑ "Michael Weston Bonney total compensation".
  17. ↑ "Ex-Cubist CEO Bonney named Third Rock partner - The Boston Globe". BostonGlobe.com. Retrieved 2016-05-23.
  18. ↑ "Former Cubist CEO Mike Bonney Joins Third Rock Ventures | Xconomy". Xconomy. 2016-01-07. Retrieved 2016-05-23.
  19. ↑ "Stealthy X4 Pharma, Aided by Termeer, Other Ex-Genzymers, Nabs $37M+ | Xconomy". Xconomy. 2015-09-01. Retrieved 2016-05-23.
  20. ↑ "Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors". www.businesswire.com. 2023-01-09. Retrieved 2023-10-05.
  21. ↑ "Michael W. Bonney - Executive Bio, Compensation History, and Contacts - Equilar Atlas". people.equilar.com. Retrieved 2016-05-24.
  22. ↑ "Bates announces gifts of $19 million to create six new endowed professorships and launch the college's new digital and computational studies program". www.bates.edu. Retrieved 2016-05-23.
  23. ↑ Wight, Patty. "Bates to Use $19 Million Donation to Launch Computer Science Program". news.mpbn.net. Retrieved 2016-02-09.
  24. ↑ "Bates announces gifts of $19 million to create six new endowed professorships and launch the college's new digital and computational studies program | News | Bates College". www.bates.edu. Retrieved 2016-02-08.
  25. ↑ "Bates receives its largest donation ever - The Boston Globe". BostonGlobe.com. Retrieved 2017-05-30.
  26. ↑ Writer, Noel K. GallagherStaff (2017-05-16). "Maine family gives $50 million 'transformational' gift to Bates College capital campaign - Portland Press Herald". Press Herald. Retrieved 2017-05-30.
  27. ↑ "Q&A: Gratitude, confidence, and optimism inspire Mike and Alison Bonney's $50 million gift to Bates". 2017-05-16. Retrieved 2017-05-30.
  28. 1 2 "President Hansen lauds Bonney '80 for philanthropy, education leadership". www.bates.edu. Retrieved 2016-05-23.
  29. ↑ "Wow! Clayton Spencer begins a new relationship with her new college". 2012-06-15. Retrieved 2016-11-28.
  30. ↑ "Who Makes Us Rare: Board of Trustees". www.rare.org. Retrieved 2020-04-10.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.